New SC32S survey study opens across Canada

A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.

“We still do not have a clear picture of who is participating in Canadian cancer clinical trials, and who may be missing,” says study co-chair Dr. Leah Lambert, Executive Director and Senior Scientist of the Nursing and Allied Health Research and Knowledge Translation at BC Cancer. “SC32S will help us understand whether we can collect these data in a way that feels appropriate and acceptable to patients, and whether our trials reflect the communities we aim to serve.”

The information collected in the survey is referred to as sociodemographic data—a combination of social and demographic information. The survey will ask CCTG trial participants about different parts of everyday life that can affect patient health.

Canadian research does not routinely collect information about the backgrounds of trial participants. Collecting this information will help researchers better understand who takes part in clinical trials and whether certain groups face barriers to participation. Learning more about the backgrounds of participants will also help ensure clinical cancer research is equitable and reflects the diversity of Canadians.

"I am excited about this study because it will help CCTG ensure that the benefits of participation in clinical trials will be available to all patients with cancer and their families across Canada," says study co-chair Dr. Michael McKenzie, Vice President Quality for BC Cancer and Clinical Professor in the Division of Radiation Oncology at University of British Columbia

Participants will also be asked whether they feel comfortable answering these types of questions, helping researchers assess the acceptability of collecting this information. The study is now accruing adult patients who are either currently being screened or already enrolled in a CCTG trial. 

“This initiative will help paint a more holistic picture of how cancer impacts lives, beyond the clinical aspects,” says Hilary Horlock, CCTG Patient Representative. “It will fill a vital gap in knowledge so health systems can plan better, more equitable clinical trials and subsequent care delivery.”

For more information:

• SC32S Patient trial information page >
• SC32S Member trial information page >